Related Experiment Video
Updated: Aug 3, 2026
Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
Published on: April 8, 2013
Comparison of therapeutic studies on regression of left ventricular hypertrophy
1Dept. of Medicine IV, University of Erlangen-Nürnberg, Germany.
Insights
Angiotensin-converting enzyme (ACE) inhibitors are most effective in reducing left ventricular mass, a risk factor for cardiovascular events. Regression of left ventricular hypertrophy through drug treatment is a key goal in managing heart health.
Area of Science:
- Cardiology
- Pharmacology
- Hypertension Research
Background:
- Left ventricular hypertrophy (LVH) is a significant, blood-pressure independent risk factor for cardiovascular morbidity and mortality.
- Increased left ventricular mass predicts cardiovascular complications in hypertensive patients and the general population.
- Regression of LVH through drug treatment is a desirable therapeutic goal.
Purpose of the Study:
- To compare the efficacy of different antihypertensive drug classes in reducing left ventricular mass.
- To investigate potential differences in the ability of various antihypertensive agents to induce LVH regression.
Main Methods:
- A meta-analysis of 109 treatment studies including 2357 patients was conducted.
- Data from studies published until December 1990 were analyzed.
- Changes in left ventricular mass and dimensions were assessed, along with correlations to blood pressure reduction.
Main Results:
- ACE inhibitors demonstrated the greatest reduction in left ventricular mass (-15%), followed by diuretics (-11.3%), calcium channel blockers (-8.5%), and beta-blockers (-8%).
- Diuretics primarily reduced ventricular diameter, while other agents mainly decreased wall thickness.
- Correlation between blood pressure reduction and LVH regression varied among drug classes, being significant only for beta-blockers.
Conclusions:
- ACE inhibitors are the most effective antihypertensive drugs for reducing left ventricular mass.
- Different antihypertensive agents impact LVH through distinct mechanisms (wall thickness vs. diameter).
- The effectiveness of LVH regression may not solely depend on blood pressure reduction.
Abstract:
In numerous studies left ventricular hypertrophy has been clearly established to be a strong, blood-pressure independent risk factor for cardiovascular morbidity and mortality. In fact, increased echocardiographic left ventricular mass has been shown to predict cardiovascular complications not only in patients with hypertension, but also in the general population. Preliminary data revealed that regression of left ventricular hypertrophy indeed reduces cardiovascular complications. As a consequence, regression of left ventricular hypertrophy by drug treatment has emerged as a desirable goal in patients with echocardiographically determined left ventricular hypertrophy. These findings raised the question, whether certain antihypertensive drugs differ in their ability to reduce left ventricular mass. To resolve this issue several comparative studies and some meta-analyses have been carried out. In a meta-analysis by Dahlöf et al., comprising 109 treatment studies published until december 1990 with a total of 2357 patients, ACE-inhibitors (-15%) were most effective in reducing left ventricular mass followed by diuretics (-11.3%), calcium channel blockers (-8.5%) and beta-blockers (-8%). Reduction in left ventricular mass was mainly due to a decrease in wall thickness except for diuretics which predominantly reduced ventricular diameter. Although reduction in blood pressure was similar for all antihypertensive agents, the correlation between changes in mean arterial pressure and effect on left ventricular mass was only significant for beta-blockers with a modest correlation for ACE-inhibitors and no clearcut relation for diuretics and calcium channel blockers.
